Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Baxter
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,150,800

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,150,800
Title:EGFR-binding modular recognition domains
Abstract: EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.
Inventor(s): Roschke; Viktor (Bethesda, MD), Lafleur; David (Washington, DC), Hilbert; David M. (Bethesda, MD), Kiener; Peter (Potomac, MD)
Assignee: Zyngenia, Inc. (Washington, DC)
Application Number:14/776,816
Patent Claims:1. A modular recognition domain (MRD) capable of binding an epidermal growth factor receptor (EGFR), wherein the MRD comprises the amino acid sequence YAEHCRQFPSDWICTLLP (SEQ ID NO: 3109).

2. A complex comprising the MRD of claim 1, wherein the MRD is fused to a heterologous protein.

3. The complex of claim 2, wherein the heterologous protein is an antibody.

4. The complex of claim 3, wherein the MRD and the antibody bind different targets.

5. The complex of claim 3, wherein the MRD and the antibody are operably linked by a linker.

6. The complex of claim 5, wherein the antibody binds EGFR.

7. The complex of claim 6, which further comprises an additional covalently bound MRD, wherein the additional covalently bound MRD binds Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3) and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3499-4094.

8. A pharmaceutical composition comprising the complex of claim 6.

9. The complex of claim 6, wherein the antibody is cetuximab.

10. The complex of claim 9, which further comprises an additional covalently bound MRD, wherein the additional covalently bound MRD binds ErbB3 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3499-4094.

11. A pharmaceutical composition comprising the complex of claim 9.

12. A complex comprising an antibody and an MRD, wherein the antibody is cetuximab and the MRD comprises the amino acid sequence YAEHCRQFPSDWICTLLP (SEQ ID NO: 3109).

13. A pharmaceutical composition comprising the complex of claim 12.

Summary for Patent:   Start Trial

PCT Information
PCT FiledMarch 14, 2014PCT Application Number:PCT/US2014/029077
PCT Publication Date:September 18, 2014PCT Publication Number:WO2014/144600

Details for Patent 10,150,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Zyngenia, Inc. (Washington, DC) 2038-12-14 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
McKinsey
Moodys
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.